High expression of polo-like kinase 4 predicts worse progression-free survival in diffuse large B cell lymphoma patients treated with R-CHOP
High PLK4 expression can reflect severe disease conditions and predict poor PFS in DLBCL patients undergoing R-CHOP treatment. This study sheds a light on the potency of PLK4 as a prognostic biomarker for DLBCL management. However, more large-sample-sized and multiple regional studies are needed for verification in the future.
Authors
- Qijie Ran (ORCID: https://orcid.org/0000-0002-7103-4705)
- Biao Xu (ORCID: https://orcid.org/0000-0001-5390-2583)
- Tao Geng (ORCID: https://orcid.org/0000-0001-9854-4097)
- Qi Wang (ORCID: https://orcid.org/0000-0003-2414-1652)
- Dehong Xu
Institutions
- Hubei Provincial Women and Children's Hospital (CN)
- Central Hospital of Wuhan (CN)
- Wuhan General Hospital of Guangzhou (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2025-10-14
- DOI
- https://doi.org/10.1186/s12957-025-04017-4
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00